Based on the Certara Inc stock forecast from 4 analysts, the average analyst target price for Certara Inc is USD 16.67 over the next 12 months. Certara Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Certara Inc is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Certara Inc’s stock price was USD 10.54. Certara Inc’s stock price has changed by -6.06% over the past week, -2.95% over the past month and -20.51% over the last year.
No recent analyst target price found for Certara Inc
No recent average analyst rating found for Certara Inc
Company Overview Certara Inc
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey. Read Less
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It of...Read More
Frequently Asked Questions About Certara Inc (CERT) Stock
Based on ratings from 4 analysts Certara Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 2 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on CERT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for CERT is USD 16.67 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 14.
CERT stock's Price/Earning ratio is 108.50.
Our analysis grades CERT stock's Price / Earning ratio at F. This means that CERT stock's Price/Earning ratio is above 64% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this CERT may be a overvalued for its sector.
The last closing price of CERT's stock was USD 10.54.
The most recent market capitalization for CERT is USD 1.84B.
Based on targets from 4 analysts, the average taret price for CERT is projected at USD 16.67 over the next 12 months.
This means that CERT's stock price may go up by +58.13% over the next 12 months.
We can't find any ETFs which contains Certara Inc's stock.
As per our most recent records Certara Inc has 1,338 Employees.
Certara Inc's registered address is 100 Overlook Center, Princeton, NJ, United States, 08540.
You can get more information about it from Certara Inc's website at https://www.certara.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Certara Inc (CERT) Stock
Based on ratings from 4 analysts Certara Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 2 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on CERT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for CERT is USD 16.67 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 14.
CERT stock's Price/Earning ratio is 108.50.
Our analysis grades CERT stock's Price / Earning ratio at F. This means that CERT stock's Price/Earning ratio is above 64% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this CERT may be a overvalued for its sector.
The last closing price of CERT's stock was USD 10.54.
The most recent market capitalization for CERT is USD 1.84B.
Based on targets from 4 analysts, the average taret price for CERT is projected at USD 16.67 over the next 12 months.
This means that CERT's stock price may go up by +58.13% over the next 12 months.
We can't find any ETFs which contains Certara Inc's stock.
As per our most recent records Certara Inc has 1,338 Employees.
Certara Inc's registered address is 100 Overlook Center, Princeton, NJ, United States, 08540.
You can get more information about it from Certara Inc's website at https://www.certara.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CERT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
